Physician profile
Mohamed Ali
NPI 1598794026
$38,697.79
in general payments reported to CMS, 2019-2025
40 companies · $17K in 2025
The $17K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $406 · 2021: $642 · 2022: $3,658 · 2023: $2,485 · 2024: $14K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $6,174 · Food and Beverage: $3,809 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,150 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,872.00 |
| Travel and Lodging | $6,174.49 |
| Food and Beverage | $3,809.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,150.00 |
| Education | $287.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $25,065.04 | 2019-2025 | Arikayce, Brinsupri |
| Mannkind Corporation | $3,150.00 | 2025 | |
| Genzyme Corporation | $2,405.73 | 2022-2025 | |
| Olympus Corporation of The Americas | $1,632.58 | 2023 | Single Use Suction Valve (Sterile), Single Use Electrosurgical Hemostatic Forceps, Single Use Electrosurgical Knife Kd-655 |
| Glaxosmithkline, LLC. | $1,158.73 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,087.27 | 2020-2025 | Airsupra, Tezspire, Fasenra |
| Medtronic, INC. | $962.94 | 2024 | Illumisite |
| Jazz Pharmaceuticals INC. | $650.58 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $430.76 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.35 | 2019-2024 | Ofev |
| Harmony Biosciences LLC | $232.69 | 2023-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $223.40 | 2021-2025 | Dupixent |
| Abbott Laboratories | $158.32 | 2022 | |
| Philips North America LLC | $133.58 | 2019-2025 | Image Management Subscription, (Ae4) Secretion Management, (8874) Incourage |
| E.R. Squibb & Sons, L.L.C. | $121.23 | 2023 | Opdivo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $98.74 | 2023-2025 | Prolastin-C Liquid |
| Genentech, INC. | $93.60 | 2022 | |
| Merck Sharp & Dohme LLC | $91.46 | 2023-2025 | Winrevair |
| Baxter Healthcare | $89.98 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $84.69 | 2020-2023 | Yupelri |
| United Therapeutics Corporation | $67.88 | 2021-2022 | |
| Genentech USA, INC. | $64.20 | 2019-2022 | |
| Advanced Respiratory, INC | $55.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $39.21 | 2022 | |
| Ani Pharmaceuticals, INC. | $31.40 | 2023 | Purified Cortrophin Gel |
| Circassia INC. | $30.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $26.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.30 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.55 | 2019 | |
| Inogen, INC. | $18.25 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.86 | 2019 | |
| Resmed Corp | $13.61 | 2025 | |
| Electromed, INC. | $12.08 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.